Skip to content

HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

Hypophosphatemia in the ICU - A One-day Point Prevalence Survey

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04201899
Acronym
HYPO-P-ICU
Enrollment
890
Registered
2019-12-17
Start date
2020-03-09
Completion date
2020-07-31
Last updated
2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill

Keywords

Phosphate

Brief summary

The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value \< 0.8 mmol/l) in international critical care settings

Detailed description

The survey will be conducted on one single day in each centre (D-day), within a week defined by the project coordinator (International PI). On D-Day, the local investigators will be asked 1. to complete questions aiming at describing their ICU (number of beds, number of patients present on D-Day, type medical/surgical/other, local phosphate reference value, presence of an hypophosphatemia treatment protocol in the ICU and route of phosphate delivery in case of hypophosphatemia) 2. to indicate how many patients had a blood phosphate \<0.08 mmol/l, for each patient with hypophosphatemia, to record the exact lowest value on D-Day, and to record age, number of days in ICU on D-Day, presence (or not) of artificial nutrition and continuous renal replacement therapy, if any phosphate administration is ongoing Data will be recorded in and electronic Case Report Form (e-CRF) in REDCap, and analysed with descriptive statistics No outcome data will be recorded (pure point-prevalence) There is no intervention

Interventions

DIETARY_SUPPLEMENTNo intervention - pure observation

Phosphate administration (yes or no)

Sponsors

European Society of Intensive Care Medicine
CollaboratorOTHER
Centre Hospitalier Universitaire Vaudois
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

blood phosphate value \< 0.8 mmol -

Exclusion criteria

Blood phosphate value \>0.8 mmol/l \-

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of hypophosphatemia1 dayBlood value \< 0.8 mmol/l

Countries

Estonia, France, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026